Janux Therapeutics (NASDAQ:JANX) Cut to Peer Perform at Wolfe Research

Wolfe Research lowered shares of Janux Therapeutics (NASDAQ:JANX) from an outperform rating to a peer perform rating in a report issued on Thursday morning, MarketBeat Ratings reports.

A number of other research firms also recently issued reports on JANX. Wedbush raised their price objective on shares of Janux Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Friday, October 16th. HC Wainwright reaffirmed a “buy” rating on shares of Janux Therapeutics in a report on Monday, October 19th. Truist Financial upped their target price on shares of Janux Therapeutics from $26.00 to $27.00 and gave the company a “buy” rating in a report on Friday, November 6th. Finally, Guggenheim dropped their price target on shares of Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $36.92.

Janux Therapeutics Trading Down 1.0%

JANX stock traded down $0.12 during trading on Thursday, reaching $11.37. The stock had a trading volume of 717,851 shares, compared to its average volume of 1,049,672. Janux Therapeutics has a 52 week low of $11.15 and a 52 week high of $35.34. The stock’s 50 day moving average is $16.80 and its two-hundred day moving average is $15.35. The firm has a market cap of $695.62 million, a PE ratio of -7.15 and a beta of 2.44.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.13. The firm had revenue of $9.29 million for the quarter, compared to the consensus estimate of $8.03 million. On average, research analysts anticipate that Janux Therapeutics will post -1.61 EPS for the current year.

Institutional Investors Weigh In On Janux Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in JANX. Diversified Trust Co increased its stake in Janux Therapeutics by 3.5% during the third quarter. Diversified Trust Co now owns 17,429 shares of the company’s stock worth $301,000 after acquiring an additional 588 shares during the last quarter. GAMMA Investing LLC raised its position in Janux Therapeutics by 67.4% during the third quarter. GAMMA Investing LLC now owns 1,642 shares of the company’s stock valued at $28,000 after purchasing an additional 661 shares during the period. Versant Capital Management Inc raised its position in Janux Therapeutics by 42.8% during the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock valued at $40,000 after purchasing an additional 784 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its stake in shares of Janux Therapeutics by 8.8% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 12,350 shares of the company’s stock valued at $213,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Bleakley Financial Group LLC lifted its stake in shares of Janux Therapeutics by 6.8% in the 3rd quarter. Bleakley Financial Group LLC now owns 21,262 shares of the company’s stock valued at $367,000 after purchasing an additional 1,363 shares during the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. The company’s research focuses on engaging a patient’s T cells to recognize and attack tumors. Janux’s proprietary platforms are designed to keep certain immune therapies inactive until they reach the tumor environment, with the goal of limiting activity in healthy tissues. Its clinical-stage programs include candidates directed at targets such as PSMA and EGFR, and its broader pipeline includes additional investigational cancer therapies.